Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway

Blood

Volumn 105, Issue 12, 2005, Pages 4776-4783

  Deriano, Ludovic ^b   Guipaud, Olivier ^b   Merle Béral, Hélène ^b   Binet, Jacques Louis ^b   Ricoul, Michelle ^b   Potocki Veronese, Gaby ^b   Favaudon, Vincent ^b   Maciorowski, Zofia ^b   Muller, Catherine ^b   Salles, Bernard ^b   Sabatier, Laure ^b   Delic, Jozo ^a  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

(2 (MORPHOLIN 4 YL) BENZO[H]CHOMEN 4 ONE; DEOXYRIBOZYME; DNA DEPENDENT PROTEIN KINASE; DOUBLE STRANDED DNA; ETOPOSIDE; KU ANTIGEN; NU 7026; PROTEIN KINASE INHIBITOR; TELOMERASE; UNCLASSIFIED DRUG; WORTMANNIN; ZINOSTATIN;

APOPTOSIS; ARTICLE; CHROMOSOME DAMAGE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA BINDING; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; ENZYME ACTIVITY; GENETIC STABILITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; RADIOSENSITIVITY;

EID: 20444416724     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-07-2888     Document Type: Article

References (66)

1. Rich T, Allen RL, Wyllie AH. Defying death after DNA damage. Nature. 2000;407:777-783.
2. Richardson C, Jasin M. Frequent chromosomal translocations induced by DNA double-strand breaks. Nature. 2000;405:697-700.
3. Smith GC, Jackson SP. The DNA-dependent protein kinase. Genes Dev. 1999;13:916-934.
4. Mimori T, Hardin JA. Mechanism of interaction between Ku protein and DNA. J Biol Chem. 1986;261:10375-10379.
5. Falzon M, Fewell JW, Kuff EL. EBP-80, a transcription factor closely resembling the human autoantigen Ku, recognizes single- to double-strand transitions in DNA. J Biol Chem. 1993;268:10546-10552.
6. Gottlieb TM, Jackson SP. The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen. Cell. 1993;72:131-142.
7. Lees-Miller SP, Chen YR, Anderson CW. Human cells contain a DNA-activated protein kinase that phosphorylates simian virus 40 T antigen, mouse p53, and the human Ku autoantigen. Mol Cell Biol. 1990;10:6472-6481.
8. Calsou P, Delteil C, Frit P, Drouet J, Salles B. Coordinated assembly of Ku and p460 subunits of the DNA-dependent protein kinase on DNA ends is necessary for XRCC4-ligase IV recruitment. J Mol Biol. 2003;326:93-103.
9. Grawunder U, Wilm M, Wu X, et al. Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells. Nature. 1997;388:492-495.
10. Critchlow SE, Bowater RP, Jackson SP. Mammalian DNA double-strand break repair protein XRCC4 interacts with DNA ligase IV. Curr Biol. 1997;7:588-598.
11. Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res. 2002;511:145-178.
12. Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 1997;91:325-334.
13. Woo RA, Jack MT, Xu Y, Burma S, Chen DJ, Lee PW. DNA damage-induced apoptosis requires the DNA-dependent protein kinase, and is mediated by the latent population of p53. Embo J. 2002;21:3000-3008.
14. Mayo LD, Turchi JJ, Berberich SJ. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res. 1997;57:5013-5016.
15. Jimenez GS, Bryntesson F, Torres-Arzayus MI, et al. DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage. Nature. 1999;400:81-83.
16. Jhappan C, Yusufzai TM, Anderson S, Anver MR, Merlino G. The p53 response to DNA damage in vivo is independent of DNA-dependent protein kinase. Mol Cell Biol. 2000;20:4075-4083.
17. Muller C, Salles B. Regulation of DNA-dependent protein kinase activity in leukemic cells. Oncogene. 1997;15:2343-2348.
18. Muller C, Christodoulopoulos G, Salles B, Panasci L. DNA-dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards. Blood. 1998;92:2213-2219.
19. Guipaud O, Deriano L, Salin H, et al. B-cell chronic lymphocytic leukaemia: a polymorphic family unified by genomic features. Lancet Oncol. 2003;4:505-514.
20. Vallat L, Magdelenat H, Merle-Beral H, et al. The resistance of B-CLL cells to DNA damage-induced apoptosis defined by DNA microarrays. Blood. 2003;101:4598-4606.
21. Masdehors P, Omura S, Merle-Beral H, et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol. 1999;105:752-757.
22. Blaise R, Alapetite C, Masdehors P, et al. High levels of chromosome aberrations correlate with impaired in vitro radiation-induced apoptosis and DNA repair in human B-chronic lymphocytic leukaemia cells. Int J Radiat Biol. 2002;78:671-679.
23. Willmore E, de Caux S, Sunter NJ, et al. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood. 2004;103:4659-4665.
24. Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, Durkacz BW. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res. 2003;63:6008-6015.
25. Hollick JJ, Golding BT, Hardcastle IR, et al. 2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-dependent protein kinase (DNA-PK). Bioorg Med Chem Lett. 2003;13:3083-3086.
26. Christodoulopoulos G, Muller C, Salles B, Kazmi R, Panasci L. Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin. Cancer Res. 1998;58:1789-1792.
27. Izzard RA, Jackson SP, Smith GC. Competitive and noncompetitive inhibition of the DNA-dependent protein kinase. Cancer Res. 1999;59:2581-2586.
28. Allalunis-Turner MJ, Barron GM, Day RS III, Dobler KD, Mirzayans R. Isolation of two cell lines from a human malignant glioma specimen differing in sensitivity to radiation and chemotherapeutic drugs. Radiat Res. 1993;134:349-354.
29. Taccioli GE, Gortlieb TM, Blunt T, et al. Ku80: product of the XRCC5 gene and its role in DNA repair and V(D)J recombination. Science. 1994;265:1442-1445.
30. Delic J, Morange M, Magdelenat H. Ubiquitin pathway involvement in human lymphocyte gamma-irradiation-induced apoptosis. Mol Cell Biol. 1993;13:4875-4883.
31. Favaudon V. Gamma-radiolysis study of the reductive activation of neocarzinostatin by the carboxyl radical. Biochimie. 1983;65:593-607.
32. Daza P, Reichenberger S, Gottlich B, Hagmann M, Feldmann E, Pfeiffer P. Mechanisms of nonhomologous DNA end-joining in frogs, mice and men. Biol Chem. 1996;377:775-786.
33. Finnie NJ, Gottlieb TM, Blunt T, Jeggo PA, Jackson SP. DNA-dependent protein kinase activity is absent in xrs-6 cells: implications for site-specific recombination and DNA double-strand break repair. Proc Natl Acad Sci U S A. 1995;92:320-324.
34. Masdehors P, Merle-Beral H, Maloum K, Omura S, Magdelenat H, Delic J. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood. 2000;96:269-274.
35. Favaudon V. On the mechanism of reductive activation in the mode of action of some anticancer drugs. Biochimie. 1982;64:457-475.
36. Frankenberg-Schwager M. Review of repair kinetics for DNA damage induced in eukaryotic cells in vitro by ionizing radiation. Radiother Oncol. 1989;14:307-320.
37. Noel G, Giocanti N, Fernet M, Megnin-Chanet F, Favaudon V. Poly(ADP-ribose) polymerase (PARP-1) is not involved in DN A double-strand break recovery. BMC Cell Biol. 2003;4:7
38. Nitiss JL, Beck WT. Antitopoisomerase drug action and resistance. Eur J Cancer. 1996;32A:958-966.
39. Mengubas K, Riordan FA, Bravery CA, et al. Ceramide-induced killing of normal and malignant human lymphocytes is by a non-apoptotic mechanism. Oncogene. 1999;18:2499-2506.
40. Han Z, Johnston C, Reeves WH, Carter T, Wyche JH, Hendrickson EA. Characterization of a Ku86 variant protein that results in altered DNA binding and diminished DNA-dependent protein kinase activity. J Biol Chem. 1996;271:14098-14104.
41. Kolesnick R, Fuks Z. Radiation and ceramide-induced apoptosis. Oncogene. 2003;22:5897-5906.
42. Mousstacchi E, Favaudon V. Cytotoxic and mutagenic effects of neocarzinostatin in wild-type and repair-deficient yeasts. Mutat Res. 1982;104:87-94.
43. Povirk LF. DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: bleomycin, neocarzinostatin and other enediynes. Mutat Res. 1996;355:71-89.
44. Adachi N, Suzuki H, Iiizumi S, Koyama H. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage. J Biol Chem. 2003;278:35897-35902.
45. Boe R, Gjertsen BT, Vintermyr OK, Houge G, Lanotte M, Doskeland SO. The protein phosphatase inhibitor okadaic acid induces morphological changes typical of apoptosis in mammalian cells. Exp Cell Res. 1991;195:237-246.
46. Gjertsen BT, Doskeland SO. Protein phosphorylation in apoptosis. Biochim Biophys Acta. 1995;1269:187-199.
47. Sturm I, Bosanquet AG, Hermann S, Guner D, Dorken B, Daniel PT. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ. 2003;10:477-484.
48. Flaman JM, Frebourg T, Moreau V, et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A. 1995;92:3963-3967.
49. Blaise R, Masdehors P, Lauge A, et al. Chromosomal DNA and p53 stability, ubiquitin system and apoptosis in B-CLL lymphocytes. Leuk Lymphoma. 2001;42:1173-1180.
50. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000;408:433-439.
51. Bullrich F, Rasio D, Kitada S, et al. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res. 1999;59:24-27.
52. Starostik P, Manshouri T, O'Brien S, et al. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res. 1998;58:4552-4557.
53. Khanna KK, Keating KE, Kozlov S, et al. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet. 1998;20:398-400.
54. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 1997;11:3471-3481.
55. Waterman MJ, Stavridi ES, Waterman JL, Halazonetis TD. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat Genet. 1998;19:175-178.
56. Heidenreich E, Novotny R, Kneidinger B, Holzmann V, Wintersberger U. Non-homologous end joining as an important mutagenic process in cell cycle-arrested cells. Embo J. 2003;22:2274-2283.
57. Reed JC. Molecular biology of chronic lymphocytic leukemia. Semin Oncol. 1998;25:11-18.
58. Gao Y, Ferguson DO, Xie W, et al. Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature. 2000;404:897-900.
59. Xu W, Liu L, Smith GC, Charles G. Nitric oxide upregulates expression of DNA-PKcs to protect cells from DNA-damaging anti-tumour agents. Nat Cell Biol. 2000;2:339-345.
60. Brady N, Gaymes TJ, Cheung M, Mufti GJ, Rassool FV. Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins. Cancer Res. 2003;63:1798-1805.
61. Difilippantonio MJ, Zhu J, Chen HT, et al. DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature. 2000;404:510-514.
62. Espejel S, Martin M, Klatt P, Martin-Caballero J, Flores JM, Blasco MA. Shorter telomeres, accelerated ageing and increased lymphoma in DNA-PKcs-deficient mice. EMBO Rep. 2004;5:503-509.
63. Gao Y, Sun Y, Frank KM, et al. A critical rale for DNA end-joining proteins in both lymphogenesis and neurogenesis. Cell. 1998;95:891-902.
64. Frank KM, Sekiguchi JM, Seidl KJ, et al. Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV. Nature. 1998;396:173-177.
65. Barnes DE, Stamp G, Rosewell I, Denzel A, Lindahl T. Targeted disruption of the gene encoding DNA ligase IV leads to lethality in embryonic mice. Curr Biol. 1998;8:1395-1398.
66. Tai YT, Teoh G, Lin B, et al. Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage. J Immunol. 2000;165:6347-6355.